OBJECTIVE: The human prohormone chromogranin A (CHGA), an index member of the granin family is processed to generate catestatin, a peptide that is hypotensive in action and modulates catecholamine release within the sympathoadrenal system. Hypertensive patients with excess sympathetic activity have diminished catestatin. Often the study of physiological consequences of human genetic variation is confounded by elements such as other variations in obligatory linkage disequilibrium with the variant being studied. Also the phenotype of the variant may be influenced by genetic background that varies amongst individuals. This study addresses the effects of a human catestatin polymorphism (rs9658667) using humanized CHGA mouse models. METHODS: We created pertinent humanized mouse models wherein the mouse Chga gene locus was replaced by the human ortholog wild-type and the variant versions. This allowed for probing of the effects of catestatin variation in vivo with controls for other variations and global genetic background. RESULTS: Both the wild-type and variant human catestatin expressing mouse models were normotensive. The variant catestatin mouse model recapitulated physiological influence of the polymorphism on autonomic traits. These mice had diminished catecholamine, attenuated stress response and increased baroreceptor slopes that would suggest reduced risk of developing hypertension. Elevated plasma glucose, a trait observed in humans was not observed in mice expressing the variant catestatin. CONCLUSION: This functional genomics approach of creating humanized mouse models to study rs9658667 polymorphism recapitulated and validated many of the human trait associations. This approach can also be applied in the study of other human gene polymorphisms.
OBJECTIVE: The human prohormone chromogranin A (CHGA), an index member of the granin family is processed to generate catestatin, a peptide that is hypotensive in action and modulates catecholamine release within the sympathoadrenal system. Hypertensivepatients with excess sympathetic activity have diminished catestatin. Often the study of physiological consequences of human genetic variation is confounded by elements such as other variations in obligatory linkage disequilibrium with the variant being studied. Also the phenotype of the variant may be influenced by genetic background that varies amongst individuals. This study addresses the effects of a humancatestatin polymorphism (rs9658667) using humanized CHGAmouse models. METHODS: We created pertinent humanized mouse models wherein the mouseChga gene locus was replaced by the human ortholog wild-type and the variant versions. This allowed for probing of the effects of catestatin variation in vivo with controls for other variations and global genetic background. RESULTS: Both the wild-type and variant humancatestatin expressing mouse models were normotensive. The variant catestatinmouse model recapitulated physiological influence of the polymorphism on autonomic traits. These mice had diminished catecholamine, attenuated stress response and increased baroreceptor slopes that would suggest reduced risk of developing hypertension. Elevated plasma glucose, a trait observed in humans was not observed in mice expressing the variant catestatin. CONCLUSION: This functional genomics approach of creating humanized mouse models to study rs9658667 polymorphism recapitulated and validated many of the human trait associations. This approach can also be applied in the study of other human gene polymorphisms.
Authors: M A Takiyyuddin; A D Baron; J H Cervenka; J A Barbosa; H P Neumann; R J Parmer; P A Sullivan; D T O'Connor Journal: J Clin Endocrinol Metab Date: 1991-03 Impact factor: 5.958
Authors: Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor Journal: J Am Soc Nephrol Date: 2008-01-30 Impact factor: 10.121
Authors: Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor Journal: Kidney Int Date: 2008-04-23 Impact factor: 10.612
Authors: Yuqing Chen; Fangwen Rao; Juan L Rodriguez-Flores; Manjula Mahata; Maple M Fung; Mats Stridsberg; Sucheta M Vaingankar; Gen Wen; Rany M Salem; Madhusudan Das; Myles G Cockburn; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Sushil K Mahata; Laurent Taupenot; Daniel T O'Connor Journal: J Am Coll Cardiol Date: 2008-10-28 Impact factor: 24.094
Authors: Ryan S Friese; Angelina E Altshuler; Kuixing Zhang; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Martin L Jirout; Rany M Salem; Jiaur R Gayen; Nitish R Mahapatra; Nilima Biswas; Mo Cale; Sucheta M Vaingankar; Hyung-Suk Kim; Maïté Courel; Laurent Taupenot; Michael G Ziegler; Nicholas J Schork; Michal Pravenec; Sushil K Mahata; Geert W Schmid-Schönbein; Daniel T O'Connor Journal: Hum Mol Genet Date: 2013-05-13 Impact factor: 6.150
Authors: Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman Journal: Hypertension Date: 2019-06 Impact factor: 10.190
Authors: Saiful A Mir; Ying Li; Jacob D Story; Soma Bal; Linda Awdishu; Anneke A Street; Ravindra L Mehta; Prabhleen Singh; Sucheta M Vaingankar Journal: J Hypertens Date: 2018-05 Impact factor: 4.844
Authors: Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar Journal: J Hypertens Date: 2020-03 Impact factor: 4.776